Oxigene plans to conduct $2.94 million at-the-market sale of shares

Deal conducted by MLV to finance preclinical studies, clinical trials

By Devika Patel

Knoxville, Tenn., Sept. 5 - Oxigene Inc. negotiated a $2.94 million at-the-market issuance sales agreement with MLV & Co. LLC on Sept. 5, according to a prospectus supplement and 8-K filed Wednesday with the Securities and Exchange Commission.

Proceeds will be used for internal research and development programs, preclinical studies, clinical trials and general corporate purposes.

Oxigene is a pharmaceutical company located in South San Francisco, Calif.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.